Oncoquest pipeline contains both IgG and IgE antibodies against the PSA antigen that can be developed from the immunotherapy of Prostate Cancer.
The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. Preclinical studies with MAb AR47.47 in animal tumor control studies showed synergistic effects for combination cyclophosphamide-IT over single agents.
Oncoquest’s anti-PSA IgE is licensed from UCLA and preclinical studies have shown that when combined with PSA, it can trigger immune activation in vitro and in vivo and significantly prolongs the survival of human FcεRIα transgenic mice challenged with PSA-expressing tumors in a prophylactic vaccination setting.
(compared to buffer control)
(compared to PSA)
(compared to PSA + anti-PSA IgG1)
PSA + anti-PSA IgG1
PSA + anti-PSA IgE
Data shown are combined from two independent experiments (n = 4 for each) with a total of 8 animals per group.
Website Design by Primal Tribe